MLMona V. Lange

Mona V. Lange

*This is an algorithmically generated author record based on publicly available information.

Mona V. Lange has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Minor differences in the untranslated regions of measles vector additional transcription units are reflected by differential immunogenicity of encoded MERS-CoV Spike antigen

    by Vishaka Tiwarekar, Aileen Ebenig, Yvonne Predota, Sabrina Schrauf, Cindy Hörner, Mona V. Lange, Mohamed R. Gadalla, Arne Auste, Csaba Miskey, Samada Muraleedharan, et al.

    The recombinant measles virus (MeV) is among those vaccine platform technologies, which are tested for the fast generation of effective vaccines against other pathogens, such as emerging virus diseases. Different live-attenuated vaccine strains have become available as backbones, with few differences. Here, we analyze how minor differences of recombinant Moraten (MV vac2 ) or Schwarz (MV Schw ) constructs have an impact on the performance of respective derived Middle East respiratory syndrome (MERS) vaccine candidates. MV vac2 or MV Schw viruses, both encoding the Spike glycoprotein (S) of the MERS-coronavirus (MERS-CoV) in an additional transcription unit (ATU) between the hemagglutinin gene and the polymerase gene L cassette, were tested. Both robustly expressed the additional gene. However, approximately twofold to threefold higher amounts of S proteins were observed in cells infected by the MV Schw -MERS-S(H) virus, correlating with the same relative ratio of S mRNA found in these cells. Exchange of the short genomic 3′ UTR ATU sequence in MV vac2 against the sequence in MV Schw enhanced gene expression by about the same factor and demonstrates causality. MeV-susceptible IFNAR −/− -CD46Ge mice vaccinated with either candidate reveal that higher relative S antigen expression by MV Schw -MERS-S(H) tended toward induction of higher specific antibody titers, but lower numbers of S antigen-specific T cells. In subsequent challenge experiments, both candidates were effective. Thus, minor differences in the genetic composition of recombinant MeV’s ATU may modulate the gene expression pattern of additionally encoded proteins that are reflected by changes in the respective immunogenicities, but which were not decisive for protection in the chosen disease model. IMPORTANCE: In case of emerging or re-emerging infections, vaccine platform technologies are needed to rapidly develop effective vaccines to aid public healthcare in pandemics. Besides mRNA vaccines, also viral platform technologies, that is, the adenovirus-derived vaccines Vaxzevria and JCOVDEN, have proven to be of immense value during the COVID-19 pandemic. For future pandemics, it is crucial to understand the factors in vector design that modulate immunogenicity. This knowledge allows the tailoring of vaccine vectors to fit specific target product profiles, for example, to build vectors which trigger an accentuated T cell or, alternatively, antibody response against an antigen of interest. Our study using the live-attenuated measles vaccine backbone as a promising example is therefore crucial in demonstrating that very minor differences in the vaccine backbone can alter the antigen expression profile of the vector-antigen system and impact the relative induction of T-cell or antibody responses against the added target antigen

  • Open Access

    Differential efficacy of first licensed western vaccines protecting without immunopathogenesis Wuhan-1-challenged hamsters from severe COVID-19

    by Aileen Ebenig, Mona V. Lange, Michelle Gellhorn Serra, Alexandra Kupke, Roland Plesker, Bingqian Qu, Richard J. P. Brown, Thorsten J. Maier, Michael D. Mühlebach

    Four COVID-19 vaccines were developed, tested, and authorized early in Europe and the US. Comirnaty and Spikevax are mRNA-based, whereas Jcovden and Vaxzevria utilize adenoviral vectors (AdV). We described a hamster model of COVID-19 utilizing Wuhan-1 strain SARS-CoV-2, in which vaccine-associated immunopathogenesis can be induced by Alum-adjuvanted Spike protein (Alum+S). Such animals were vaccinated with the authorized vaccines or Alum+S, challenged, and examined. All vaccinated hamsters produced antibodies targeting S. Neutralizing antibodies (nAb) were induced only by authorized vaccines. While nAbs were present after one vaccination with AdV-vaccines, mRNA vaccines needed a boost immunization. Upon challenge, all authorized vaccines protected from severe disease. Less tissue damage and no live virus (one exception) were detectable in the lungs. In contrast, Alum+S immunized hamsters developed VAERD. Our data reveal the absence of induction of VAERD by early commercial vaccines in hamsters, while animals´ immune responses and protection seem to match the clinical vaccine efficacy.


  • Open Access

    Hamster Model of Severe COVID-19 Demonstrates Differential Efficacy of first Licensed Western Vaccines in the Absence of Immunopathogenesis

    by Michael Mühlebach, Aileen Ebenig, Mona Lange, Michelle Gellhorn Serra, Alexandra Kupke, Roland Plesker, Thorsten Maier

    To combat the COVID-19 pandemic, vaccines have been developed, tested and approved in less than one year. Four vaccines using two technology platforms were authorized early in Europe and the US. Comirnaty and Spikevax are mRNA-based, whereas Jcovden and Vaxzevria utilize adenoviral vectors (AdV). We already described a hamster model of severe COVID-19, in which vaccine-associated immunopathogenesis can be induced by Alum-adjuvanted Spike protein. Such animals were vaccinated here with the early authorized vaccines, challenged, and examined for immunopathogenesis in comparison to Alum+S-vaccinated or naïve hamster after challenge. All vaccinated hamsters produced antibodies binding (bAb) to SARS-CoV-2 Spike, while neutralizing antibodies (nAb) were induced only by the authorized vaccines. Among those, uniform induction of nAbs by mRNA vaccines needed a second dose. Using AdV-based vaccines, nAbs were mostly abundant after just one vaccination, but boostability was low. Upon challenge, Alum+S immunized animals were not protected and developed VAERD. In contrast, all authorized vaccines protected from severe disease, but transient initial weight loss was observed. In accordance with lower nAb titers, a tendency for higher weight loss became evident with Vaxzevria. Histopathology revealed less tissue damage after immunization with the authorized vaccines, with two animals revealing unaffected, healthy lungs. No live virus was detectable in lung tissue in those vaccine groups, except for one animal with Vaxzevria. Our data reveal absence of induction of VAERD by the authorized vaccines in a susceptible hamster model, while the induced immune responses and observed degree of protection seem to match the clinical vaccine efficacy.

  • Open Access

    Versatility of live-attenuated measles viruses as platform technology for recombinant vaccines

    by Aileen Ebenig, Mona V. Lange, Michael D. Mühlebach

    Live-attenuated measles virus (MeV) has been extraordinarily effective in preventing measles infections and their often deadly sequelae, accompanied by remarkable safety and stability since their first licensing in 1963. The advent of recombinant DNA technologies, combined with systems to generate infectious negative-strand RNA viruses on the basis of viral genomes encoded on plasmid DNA in the 1990s, paved the way to generate recombinant, vaccine strain-derived MeVs. These live-attenuated vaccine constructs can encode and express additional foreign antigens during transient virus replication following immunization. Effective humoral and cellular immune responses are induced not only against the MeV vector, but also against the foreign antigen cargo in immunized individuals, which can protect against the associated pathogen. This review aims to present an overview of the versatility of this vaccine vector as platform technology to target various diseases, as well as current research and developmental stages, with one vaccine candidate ready to enter phase III clinical trials to gain marketing authorization, MV-CHIK.